Insider Selling: Clene (NASDAQ:CLNN) Major Shareholder Sells 3,195 Shares of Stock

Clene Inc. (NASDAQ:CLNN) major shareholder Chidozie Ugwumba sold 3,195 shares of the stock in a transaction on Thursday, January 8th. The shares were sold at an average price of $6.09, for a total value of $19,457.55. Following the completion of the sale, the insider owned 750,367 shares of the company’s stock, valued at approximately $4,569,735.03. This represents a 0.42% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Chidozie Ugwumba also recently made the following trade(s):

• On Monday, January 12th, Chidozie Ugwumba sold 32,705 shares of Clene stock. The stock was sold at an average price of $5.50, for a total value of $179,877.50.
• On Friday, January 9th, Chidozie Ugwumba sold 9,075 shares of Clene stock. The stock was sold at an average price of $6.27, for a total value of $56,900.25.
• On Wednesday, January 7th, Chidozie Ugwumba sold 3,938 shares of Clene stock. The shares were sold at an average price of $6.29, for a total value of $24,770.02.
• On Tuesday, January 6th, Chidozie Ugwumba sold 3,111 shares of Clene stock. The shares were sold at an average price of $6.04, for a total value of $18,790.44.
• On Monday, January 5th, Chidozie Ugwumba sold 5,869 shares of Clene stock. The stock was sold at an average price of $5.87, for a total value of $34,451.03.
• On Friday, January 2nd, Chidozie Ugwumba sold 4,015 shares of Clene stock. The stock was sold at an average price of $5.73, for a total value of $23,005.95.
• On Wednesday, December 31st, Chidozie Ugwumba sold 13,095 shares of Clene stock. The shares were sold at an average price of $5.81, for a total transaction of $76,081.95.
• On Tuesday, December 30th, Chidozie Ugwumba sold 4,138 shares of Clene stock. The stock was sold at an average price of $6.03, for a total transaction of $24,952.14.
• On Monday, December 29th, Chidozie Ugwumba sold 8,096 shares of Clene stock. The shares were sold at an average price of $5.95, for a total transaction of $48,171.20.
• On Tuesday, December 23rd, Chidozie Ugwumba sold 6,831 shares of Clene stock. The shares were sold at an average price of $6.27, for a total transaction of $42,830.37.

Clene Price Performance

Clene stock traded down $1.21 during midday trading on Monday, hitting $5.18. 359,860 shares of the stock were exchanged, compared to its average volume of 108,848. Clene Inc. has a 1 year low of $2.28 and a 1 year high of $13.50. The firm has a market cap of $53.53 million, a P/E ratio of -1.53 and a beta of 0.87. The company has a 50 day moving average price of $7.68 and a two-hundred day moving average price of $6.44.

Clene (NASDAQ:CLNN) last posted its quarterly earnings data on Thursday, November 13th. The company reported ($0.85) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.25). The business had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.06 million. As a group, analysts predict that Clene Inc. will post -5.19 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts have issued reports on the company. D. Boral Capital restated a “buy” rating and set a $23.00 price objective on shares of Clene in a report on Friday. UBS Group reissued a “buy” rating on shares of Clene in a research report on Wednesday, December 3rd. Weiss Ratings restated a “sell (d-)” rating on shares of Clene in a research note on Tuesday, October 14th. Finally, Benchmark reiterated a “buy” rating on shares of Clene in a research note on Thursday, December 4th. Six analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $32.60.

Institutional Trading of Clene

Several institutional investors have recently added to or reduced their stakes in the business. Lunt Capital Management Inc. raised its holdings in shares of Clene by 71.2% during the second quarter. Lunt Capital Management Inc. now owns 51,010 shares of the company’s stock worth $199,000 after purchasing an additional 21,217 shares during the period. Jane Street Group LLC acquired a new position in shares of Clene in the 2nd quarter valued at about $47,000. Scoggin Management LP boosted its holdings in shares of Clene by 42.8% in the 2nd quarter. Scoggin Management LP now owns 142,750 shares of the company’s stock valued at $558,000 after buying an additional 42,750 shares during the period. Finally, Jones Financial Companies Lllp bought a new stake in shares of Clene during the 3rd quarter valued at about $29,000. Institutional investors own 23.28% of the company’s stock.

Clene Company Profile

Clene (NASDAQ: CLNN), also known as Clene Nanomedicine, is a clinical-stage biopharmaceutical company developing proprietary nanoparticle therapies aimed at treating neurodegenerative and demyelinating disorders. The company’s flagship product, CNM-Au8, is a suspension of catalytic gold nanocrystals designed to enhance cellular energy metabolism, promote remyelination, and reduce oxidative stress. Clene’s platform leverages the unique physicochemical properties of its nanoparticles to support neuronal health, with a focus on diseases that currently lack effective disease-modifying treatments.

Clene’s lead candidate, CNM-Au8, is undergoing multiple clinical trials targeting conditions such as amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).